| 发明名称 |
Combination of CD37 antibodies with ICE |
| 摘要 |
The present invention relates to immunotherapies that are based on depletion of CD37-positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual/patient using a combination of CD37 antibody/antibodies and ICE. The combination of CD37 antibodies and ICE is shown to have improved anti-tumor efficacy compared to single agent treatment. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity. |
| 申请公布号 |
US8992915(B2) |
申请公布日期 |
2015.03.31 |
| 申请号 |
US201313894743 |
申请日期 |
2013.05.15 |
| 申请人 |
Boehringer Ingelheim International GmbH |
发明人 |
Heider Karl-Heinz;Baum Anke;Russell Charlotte Astrid |
| 分类号 |
A61K39/395;A61K31/555;C07K16/28;A61K31/675;A61K31/661;A61K31/7048;A61K39/00 |
主分类号 |
A61K39/395 |
| 代理机构 |
|
代理人 |
Morris Michael P.;Kershner David L.;Patel Usha R. |
| 主权项 |
1. A method for the treatment of a patient suffering from chronic lymphocytic leukemia (CLL) or B-cell non-Hodgkin's lymphoma (B-NHL), the method comprising administering to the patient (a) a CD37 antibody and (b) a combination chemotherapy regimen comprising ICE (ifosfamide, carboplatin, and etoposide (or etoposide phosphate)), whereby the CD37 antibody comprises:
a) a variable heavy chain comprising CDRs having the SEQ ID NOs: 15, 16 or 21, and 17, and b) a variable light chain comprising CDRs having the SEQ ID NOs: 18, 19 and 20. |
| 地址 |
Ingelheim am Rhein DE |
